Status:
COMPLETED
Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
Lead Sponsor:
Albert Koong
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine
Detailed Description
In this study, we propose to combine stereotactic body radiotherapy (SBRT) with standard gemcitabine chemotherapy. We hypothesize that earlier administration of systemic chemotherapy may prolong the i...
Eligibility Criteria
Inclusion
- Pancreatic tumors not to exceed 10 cm in greatest axial dimension
- Histologically confirmed malignancies of the pancreas
- Unresectable by CT criteria or exploratory laparotomy or laparoscopy
- Patients with metastatic disease may be treated if they are symptomatic from the primary tumor
- Performance status of 0, 1, or 2
- No chemotherapy two weeks prior or two weeks following radiosurgery
Exclusion
- patients who have had prior radiotherapy to upper abdomen
- patients receiving any prior pancreatic cancer therapy
- children, pregnant, and breastfeeding women, and lab personnel are excluded
- uncontrolled intercurrent illnesses
- any concurrent malignancy
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00350142
Start Date
April 1 2006
End Date
October 1 2008
Last Update
February 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305